Maxim Group Lowers Context Therapeutics (NASDAQ:CNTX) Price Target to $4.00

Context Therapeutics (NASDAQ:CNTX) had its price objective reduced by analysts at Maxim Group from $8.00 to $4.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price objective indicates a potential upside of 490.84% from the company’s current price.

Other analysts have also recently issued reports about the stock. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Piper Sandler lifted their target price on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Wall Street Zen cut shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Context Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Stock Down 0.3%

Shares of Context Therapeutics stock traded down $0.00 on Tuesday, reaching $0.68. The stock had a trading volume of 4,507,238 shares, compared to its average volume of 1,424,900. The company has a 50 day moving average price of $2.30 and a 200 day moving average price of $2.10. Context Therapeutics has a 1 year low of $0.56 and a 1 year high of $3.62. The stock has a market capitalization of $62.20 million, a P/E ratio of -1.61 and a beta of 1.61.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. On average, analysts forecast that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Several hedge funds have recently made changes to their positions in the business. State Street Corp lifted its position in shares of Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Context Therapeutics during the first quarter worth about $51,000. Blue Owl Capital Holdings LP increased its stake in shares of Context Therapeutics by 0.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after buying an additional 25,000 shares during the period. Virtu Financial LLC purchased a new stake in shares of Context Therapeutics during the fourth quarter worth approximately $43,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Context Therapeutics during the fourth quarter worth approximately $68,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.